臨床検査51巻10号

2007年10月発行

今月の主題 白血球 総説

抗菌ペプチドとその作用メカニズム

著者： 長岡功¹ François²

所属機関： ¹順天堂大学医学部生化学・生体防御学 ²順天堂大学医学部アトピー疾患研究センター

ページ範囲：P.1037 - P.1045

　デフェンシン(defensin)やcathelicidinなどのペプチドは，はじめ抗菌作用をもつ物質として見いだされたことから自然免疫にかかわる分子として注目されてきた．しかし，その後の研究によって，これらのペプチドが獲得免疫にも関与する可能性が示唆され，今では自然免疫と獲得免疫の橋渡しをする生体防御分子として考えられている．さらに，それらの抗菌作用に着目して，ペプチド誘導体の感染症に対する効果が臨床的に評価されはじめている．

参考文献

１) Hancock REW, Chapple DS：Peptide antibiotics. Antimicrob Agents Chemother　43：1317-1323, 1999

２) Jenssen H, Hamill P, Hancock REW：Peptide antimicrobial agents. Clin Microbiol Rev　19：491-511, 2006

３) Bowdish DME, Davidson DJ, Hancock REW：A re-evaluation of the role of host defence peptides in mammalian immunity. Curr Protein Pept Sci　6：35-51, 2005

４) Ganz T：Defensins：antimicrobial peptides of innate immunity. Nat Rev Immunol　3：710-720, 2003

５) Zanetti M, Gennaro R, Romeo D：Cathelicidins：a novel family with a common proregion and a variable C-terminal antimicrobial domain. FEBS Lett　374：1-5, 1995

６) Niyonsaba F, Nagaoka I, Ogawa H：Human defensins and cathelicidins in the skin：beyond direct antimicrobial properties. Crit Rev Immunol　26：545-575, 2006

７) Tsutsumi-Ishii Y, Hasebe T, Nagaoka I：Role of CCAAT/enhancer-binding protein site in transcription of human neutrophil peptide-1 and-3 defensin genes. J Immunol　164：3264-3273, 2000

８) Agerberth B, Charo J, Werr J, et al：The human antimicrobial and chemotactic peptide LL-37 and α-defensins are expressed by specific lymphocyte and monocyte populations. Blood　96：3086-3093, 2000

９) Ghosh D, Porter E, Shen B, et al：Paneth cell trypsin is the processing enzyme for human defensin-5. Nat Immunol　3：583-590, 2002

10) Wilson CL, Quellette AJ, Satchell DP, et al：Regulation of intestinal α-defensin activation by the metalloproteinase matrilysin in innate host defense. Science　286：113-117, 1999

11) Pazgier M, Hoover DM, Yang D, et al：Human β-defensins. Cell Mol Life Sci　63：1294-1313, 2006

12) Tran D, Tran PA, Tang YQ, et al：Homodimeric θ-defensins from Rhesus macaque leukocytes. J Biol Chem　277：3079-3084, 2002

13) Nguyen TX, Cole AM, Lehrer RI：Evolution of primate θ-defensins：a serpentin path to a sweet tooth. Peptides　24：1647-1654, 2003

14) Pu¨tsep K, Carlsson G, Boman HG, et al：Deficiency of antibacterial peptides in patients with morbus Kostmann：an observation study. Lancet　360：1144-1149, 2002

15) Wehkamp J, Salzman NH, Porter E, et al：Reduced Paneth cell α-defensins in ileal Crohn's disease. Proc Natl Acad Sci USA　102：18129-18134, 2005

16) Ong PY, Ohtake T, Brandt C, et al：Endogenous antimicrobial peptides and skin infections in atipic dermatitis. N Engl J Med　347：1151-1160, 2002

17) Du¨rr UHN, Sudheendra US, Ramamoorthy A：LL-37, the only human member of the cathelicidin family of antimicrobial peptides. Biochim Biopys Acta　1758：1408-1425, 2006

18) Nagaoka I, Hirata M, Sugimoto K, et al：Evaluation of the expression of human CAP18 gene during neutrophil maturation in the bone marrow. J Leukoc Biol　64：845-852, 1998

19) Larrick JW, Hirata M, Zhong J, et al：Anti-microbial activity of human CAP18 peptides. Immunotechnology　1：65-72, 1995

20) Turner J, Cho Y, Dinh NN, et al：Activities of LL-37, a cathelin-associated antimicrobial peptide of human neutrophils. Antimicrob Agents Chemother　42：2206-2214, 1998

21) Dorschner RA, Lopez-Garcia B, Peschel A, et al：The mammalian ionic environment dictates microbial susceptibility to antimicrobial defense peptides. FASEB J　20：35-42, 2006

22) Bals R, Weiner DJ, Meegalla RL, et al：Transfer of a cathelicidin peptide antibiotic gene restores bacterial killing in a cystic fibrosis xenograft model. J Clin Invest　103：1113-1117, 1999

23) Brogden KA：Antimicrobial peptides：pore fromers or metabolic inhibitors in bacteria ? Nat Rev Microbiol　3：238-250, 2005

24) Matsuzaki K：Why and how are peptide-lipid interactions utilized for self defence ? Biochem Soc Trans　29：598-601, 2001

25) Nagaoka I, Kuwahara-Arai K, Tamura H, et al：Augmentation of the bactericidal activities of human cathelicidin CAP18/LL-37-derived antimicrobial peptides by amino acid substitutions. Inflamm Res　54：66-73, 2005

26) Nagaoka I, Hirota S, Yomogida S, et al：Synergistic actions of antibacterial neutrophil defensins and cathelicidins. Inflamm Res　49：73-79, 2000

. J Dermatol Sci　40：123-132, 2005

cells. J Immunol　167：3329-3338, 2001

29) Scott MG, Vreugdenhil ACE, Buurman AW, et al：Cationic antimicrobial peptides block the binding of lipopolysaccharide (LPS) to LPS binding protein. J Immunol　164：549-553, 2000

30) Nagaoka I, Hirota S, Niyonsaba F, et al：Augmentation of the lipopolysaccharide-neutralizing activities of human cathelicidin CAP18/LL-37-derived antimicrobial peptides by replacement with hydrophobic and cationic amino acid residues. Clin Dign Lab Immunol　9：972-982, 2002

31) Yang D, Chen Q, Hoover DM, et al：Many chemokines including CCL20/MIP-3α display antimicrobial activity. J Leukoc Biol　74：448-455, 2003

cell-derived dendritic cells express functional receptors for platelet activating factor. FEBS Lett　418：98-100, 1997

33) Niyonsaba F, Ushio H, Nakano N, et al：Antimicrobial peptides human β-defensins stimulate epidermal keratinocytes migration, proliferation and production of proinflammatory cytokines and chemokines. J Invest Dermatol　127：594-604, 2007

. J Immunol　176：3044-3052, 2006

35) 長岡功，田村弘志，平田陸正：内因性抗菌ペプチドを用いた感染症治療を目指して．化学療法の領域　21：105-112, 2005

36) Perron GG, Zasloff M, Bell G：Experimental evolution of resistance to an antimicrobial peptide. Proc R Soc Lond B Biol Sci　273：251-256, 2006